Company Atossa Genetics Inc Nasdaq
Equities
US04962H2094
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 30/11/08 |
Steven Quay
CEO | Chief Executive Officer | 73 | 30/11/08 |
Heather Rees
DFI | Director of Finance/CFO | - | 31/12/16 |
Arezoo Mirad
CTO | Chief Tech/Sci/R&D Officer | - | 12-03 |
Richard Graydon
CTO | Chief Tech/Sci/R&D Officer | - | 24/10/22 |
Delly Behen
ADM | Chief Administrative Officer | - | 31/12/13 |
Eric van Zanten
IRC | Investor Relations Contact | - | 06/12/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 30/11/08 |
Director/Board Member | 66 | 28/02/14 | |
H. Remmel
BRD | Director/Board Member | 72 | 31/01/12 |
Shu-Chih Chen
FOU | Founder | 62 | 30/11/08 |
Stephen Galli
BRD | Director/Board Member | 77 | 30/06/11 |
Jonathan Finn
BRD | Director/Board Member | 50 | 11-07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 126,624,110 | 125,230,652 ( 98.90 %) | 1,320,046 ( 1.042 %) | 98.90 % |
Stock B | 0 | 582 | 0 | 0 |
Company contact information
Atossa Therapeutics, Inc.
107 Spring Street
98104, Seattle
+206 588 0256
http://www.atossatherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |